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Expression of a nonmuscie myosin heavy chain in glomerular
cells differentiates various types of glomerular disease in rats
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Expression of a nonmuscie myosin heavy chain in glomerular cells
differentiates various types of glomerular disease in rats. To characterize
the phenotypic modulation of mesangial and glomerular epithelial cells,
we investigated the expression of a nonmuscie type myosin heavy chain,
SMemb, and a-smooth muscle actin (a-SM actin) in rat experimental
glomerular diseases, which included anti-Thy 1 nephritis, 5/6 nephrec-
tomy, diabetes, and anti-glomerular basement membrane nephritis.
SMemb was only slightly expressed in normal glomerular epithelial cells
but not in mesangial cells. In the anti-Thy 1 nephritis rats, both SMemb
and a-SM actin were most conspicuously induced in mesangial cells.
However, the expression profile was shifted from a-SM actin to SMemb
dominant pattern over the course of glomerulonephritis. The expression
of SMemb was also increased in epithelial cells in this model. In the other
three models, glomerular cells did not express a-SM actin, but did so for
SMemb. In the nephrectomized and the diabetic rats SMemb was newly
expressed in mesangial cells at earlier stages, but at later stages was
remarkably enhanced in epithelial cells when severe glomerular hypertro-
phy developed. In the anti-GBM nephritis rats, SMemb expression was
increased in cpithelial cells. In all models examined, mesangial and
epithelial expression of SMemb was confirmed by immunoelectron mi-
croscopy, and enhanced expression of SMemb mRNA in glomeruli was
verified by RNase protection assay. We conclude from these results that
glomerular cells change their phenotypes differently depending on various
types of glomerular diseases. These phenotypic changes in glomcrular cells
can be revealed by the combined immunostaining for SMemb and a-SM
actin. SMemb is especially useful to detect both mesangial and glomerular
epithelial cell activation in these glomerular disease models. Understand-
ing the functional difference and regulatory mechanisms of these cytoskel-
etal proteins will provide insight into the pathogenesis and progression of
glomerular diseases.
There is increasing evidence that mesangial cells are activated
and show phenotypic modulation with enhanced expression of
a-smooth muscle actin (a-SM actin) in various types of glomeru-
tar diseases [reviewed in 1—4]. The activated mesangial cells also
change their character to the secretory phenotype and release a
multitude of inflammatory mediators [5]. These pathological
events are considered to be associated with mesangial cell prolif-
eration, which leads to glomerulosclerosis. Further studies by
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renal biopsy showed that mesangial cells also express nerve
growth factor receptor (NGF) in a variety of glomerular diseases
[6]. However, glomerular expression of either a-SM actin and
NGF was found to be limited to the mesangial cell. Recent studies
have shown that epithelial cells are also activated frequently and
play an important role in the progression of glomerular diseases
[7—111, which indicates that sensitive markers for both mesangial
cell and epithelial cell activation need to be developed.
We previously isolated and characterized eDNA clones for
three types of myosin heavy chain (MHC) isoforms: SMI, SM2,
and SMemb. SM1 and SM2 are specific to smooth muscle cells,
whereas SMemb is a nonmuscle type MHC. Although SMemb is
ubiquitously expressed in many types of nonmuscie cells, it is most
abundant in smooth muscles of embryonic aortas, and is down-
regulated with vascular development [12—15]. Preliminary obser-
vations in our laboratory have shown that SMemb is expressed in
many activated mesenchymal cells in vivo, including smooth
muscle cells and fibroblasts [16].
In the present study, to characterize glomerular cell activation
in glomerulopathy, and to differentiate various types of glomeru-
tar diseases, we examined the expression of both SMemb and
a-SM actin in four glomerular disease models in the rat. Our
results suggest that: (1) injured glonierular cells change their
phenotypes heterogeneously depending on the type or stage of
diseases; (2) SMemb expression is closely correlated with mesan-
gial and epithelial cell activation, whereas glomerular expression
of a-SM actin is limited to activated mesangial cells.
Methods
Anti-Thy 1 nephritis model
Mesangioproliferative glomerulonephritis was induced by intra-
venous injection of anti-Thy 1.1 antiserum (22211D; 0.2 ml/100 g
body wt; Pharmingen, San Diego, CA, USA) into 55 female
Wistar rats weighing 160 to 200 g. Eleven rats were sacrificed for
determination of SMemb expression in the kidney at days 1, 3, 5,
8 or 21. As controls, the same number of female Wistar rats of the
same body wt were intravenously administered with physiological
saline.
Other disease models
5/6 Nephrectomy. Subtotal nephrectomy was achieved by right
uninephrectomy, and after two weeks of recovery, resection of the
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upper and lower thirds of the left kidney in 55 male Wistar rats
weighing 160 to 200 g was conducted [17]. Eleven rats were
sacrificed for determination of SMemb expression at days 3, 10,
and weeks 4, 8, or 16. As controls, the same number of male
Wistar rats of the same body wt were sham-operated.
Diabetes. Diabetes mellitus was induced by intravenous injec-
tion of streptozotocin (S-U 130; 65 mg/kg body wt; Sigma Chemical
Co., St. Louis, MO, USA) dissolved in citric acid buffer (pH 4.0)
through tail veins in 44 male Wistar rats weighing 160 to 200 g
[18]. Eleven rats were sacrificed for determination of SMemb
expression at days 3, 10, or weeks 4 or 8. As controls, the same
number of male Wistar rats of the same body wt were intrave-
nously administered with physiological saline.
Anti-glomerular basement membrane (GBM) nephritis. Glomer-
ulonephritis was induced by intravenous injection of anti-GBM
antiserum [19] (1.5 mi/lOU g body wt) into 11 male Sprague-
Dawley (SD) rats weighing 160 to 200 g. Eleven rats were
sacrificed for determination of SMemb expression at day 7. As
controls, the same number of male SD rats of the same body wt
were intravenously administered with physiological saline.
All rats were fed standard rat pellets and had free access to tap
water. Before sacrifice, the systolic blood pressure was measured
by the tail cuff (Natume Co., Tokyo, Japan). The rats were then
housed individually in metabolic cages (Natume Co.) for collec-
tion of 24 hour-urine samples in order to measure daily protein
excretion. Urinary protein was measured by the pyrogallol red
method [20]. In the diabetic rats, the blood glucose and urinary
glucose excretion were also measured. Of 11 rats in each model,
five rats were provided for conventional histological and immu-
nohistochemical examinations. Immunoelectron microscopic lo-
calization of SMemb expression was performed in one rat, and
RNase protection assay in five rats.
Histological and immunohistochemical examination
The kidneys were removed and fixed in 95% ethanol with 1%
acetic acid at 4°C for four hours. The specimens were then
dehydrated and embedded in paraffin. One-j.tm thick serial sec-
tions were obtained for conventional histological study (hematox-
ylin and eosin or periodic acid-Schiff) or immunohistochemistiy.
Four monoclonal antibodies were used for immunohistochemical
evaluation: mouse anti-rabbit SM2, mouse anti-rabbit SMemb
[15, 161 (SM1 was not revealed in the ethanol fixed rat kidneys by
the anti-SM1 antibody), mouse anti-human a-SM actin (M851,
DAKO A/S, Denmark), and mouse anti-human proliferating cell
nuclear antigen/cyclin (PCNA) (M879, DAKO A/S). All primary
antibodies used in the present study have been shown to have
cross reactivity to the rat antigens [2 1—23]. Immunohistochemical
study was performed by the labeled streptavidin biotin kit (DAKO
Co.) [24]. Sections were preincubated with 3% hydrogen peroxide
and 0.1% sodium azide to reduce non-specific reactions. Primary
antibodies against SM2, SMemb, a-SM actin or PCNA were
applied at a dilution of 1:50 to 1:100 in Tris-buffered saline with
Table 1. The blood pressure and the urinary protein excretion
Blood pressure
mm Hg
Urinary protein excretion
mg/day
ATS-3 Control
ATS
—
—
2 0
211 42"
ATS-5 Control
ATS
—
—
3 1
132 12°
ATS-8 Control
ATS
—
—
3 1
41±17°
NX-4 SHAM
OP
107±5
106±4
7±2
89±8a
NX-8 SHAM
OP
108 11
128±8
12 3
182±19a
NX-16 SHAM
OP
104 6
120 10
16 4
237 25
DM-4 Control
DM
109 7
106±6
5 1
67±1P
DM-8 Control
DM
89 4
85±15
13 2
98±4k'
GBM Control
GBM
—
—
11 3
372±2a
Abbreviations are: ATS-3, 5, and 8, the anti-Thy 1 nephritis rats at days
3, 5, and 8; NX-4, 8 and 16, the nephrectomized rats at weeks 4, 8, and 16;
DM4 and 8, the diabetic rats at weeks 4 and 8; GBM, the anti-GBM rats.
Values are mean SEM (N = 5).
P < 0.001 vs. control
bp < 0.01 vs. control
P < 0.1 vs. control
Tween 20 (TBST) and incubated for 20 minutes at room temper-
ature. Sections were incubated with biotinylated rabbit anti-
mouse immunoglobulin (E464, DAKO A/S) for 30 minutes and
then incubated with horseradish peroxidase-labeled streptavidin
solution for 10 minutes. The slides were rinsed in TBST after each
incubation step. Peroxidase was visualized by 3,3'-diaminobenzi-
dine tetrahydrochloride (0.2 mg/mi; Sigma Chemical Co., St.
Louis, MO, USA) as chromogen with 0.014% hydrogen peroxide
as substrate. The slides were washed in tap water and counter-
stained with hematoxylin, dehydrated and mounted. Negative
controls were induced by omission of either of the primary
antibodies in the staining procedure.
Analysis of immunohistochemistiy
SMemb and a-SM actin expression score. Approximately 100
glomeruli for each kidney were graded according to degree of
SMemb and a-SM actin expression. Glomerular expression was
graded semiquantitatively according to the following procedure
described by Kimura et a! [25]: 0 = no expression; 1 = mild
expression (less than 30% of a glomerular area); 2 = moderate
expression (30% to 60% of a glomerular area); 3 = marked
expression (more than 60% of a glomerular area).
This grading was performed by one observer (J.H.) in a blind
fashion with coded slides. A weighted composite expression score
was then calculated for each kidney according to the following
Fig. 1. Immunohistochemical glomerular staining for SMemb (A-D) and a-SM actin (E-H) in the anti-Thy 1 nephritis rats. At day 5, SMemb was newly
expressed in mesangial cells (A). SMemb expression was greatest at day 8 (B), and decreased at day 21(C). In the control rats, SMemb was slightly
expressed in glomerular epithelial cells (D). a-SM actin was strongly positive at day 5 (E), and expressed extensively at day 8 (F). a-SM actin expression
disappeared earlier than SMemb at day 21(G). Normal glomeruli did not express a-SM actin, although a-SM actin expression could be observed in the
renal arteries and arterioles (H) (original magnification: x260).
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Fig. 2. Semiquantitative evaluation of immunohistochemistiy in the anti-
Thy 1 nephritis rats. (A) SMemb expression scores in the anti-Thy 1
nephritis rats. The scores were higher in the anti-Thy I nephritis rats
(shaded column) (N = 5) than in the controls (unshaded column) (N = 5)
at days 5, 8, and 21. (B) a-SM actin expression scores in the anti-Thy 1
nephritis rats. The scores were higher in the anti-Thy 1 nephritis rats than
in the controls at all points. (C) The number of PCNA-positive cells per
glomerular cross section in the anti-Thy 1 nephritis rats. PCNA-positive
cells peaked at day 5, and then decreased. *p < 0.05, **p < 0.01.
formula: expression score = [1 X (number of grade 1 glomeruli)
+ 2 x (number of grade 2 glomeruli) + 3 X (number of grade 3
glomeruli)]/(number of glomeruli observed). At the light micro-
scopic level, we regarded peripheral cells delineating the glomer-
ular tuft as epithelial cells.
RNase protection assay
Rats were sacrificed under ether anesthesia and kidneys were
removed, and decapsulated. Glomeruli were isolated by differen-
tial sieving at 4°C using PBS [26]. Total RNA was extracted by
RNA Zol B (Bioteck Laboratories Inc., Houston, TX, USA)
according to the acid guanidinium thiocyanate phenol-chloroform
method [27]. The cRNA probe for rat SMemb mRNA (riboprobe
1) was produced by polymerase chain reaction from the cDNA of
rat fibroblast, using primers designed for SMemb-specific se-
quences which are conserved in rabbit and human. The amplified
DNA was subcloned into pCR II (In vitrogen, San Diego, CA,
USA) and sequenced by the Taq dye terminator cycle sequencing
kit (Applied Biosystems Inc., Foster City, CA, USA). Homology
of amino acid sequence of rat SMemb was 80% and 84% with
human and rabbit, respectively. In the assay for SMemb mRNA,
we included a cRNA probe for human 18S ribosomal RNA (pT7
RNA 18S, Ambion Inc., Austin, TX, USA) (riboprobe 2) to
* PCNA-positive cells in glomerular tufts. Proliferation was ex-
pressed as the number of PCNA-positive cells per glomerular
cross section. Quantitation of PCNA-positive cells was performed
by counting all positive cells within the glomerular tufts and
dividing by the number of glomeruli present in each section [1].
Determination of glomerular area
The glomerular areas were measured by tracking the outline of
glomerular tufts with a computer-aided video manipulator
(Hamamatsu-Photonics Co., Hamamatsu, Japan). For this pur-
pose, 25 nonsclerotic glomeruli were chosen separately from outer
and inner cortexes (total 50 glomeruli) for each rat.
Immunoelectron microscopy
B
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The kidneys were fixed by perfusing periodate-lysine-parafor-
maldehyde (PLP) solution, then cut into three-mm thick slices
* * and immersed in PLP solution overnight at 4°C. After rinsing with
phosphate buffered saline (PBS), the tissue was processed for
electron microscopic immunohistochemistry using the pre-em-
bedding immunoperoxidase procedure. Fifty-pm sections were
cut from the tissue slides on a vibratome (Microsclicer, Dosaka
Co., Osaka, Japan), washed with 50 mivi NH4C1 in PBS, and
permeabilized by incubation for one hour in PBS containing 1%
ovalbumin, 0.2% gelatin, and 0.05% saponin (solution A). The
sections were incubated overnight at 4°C with primary antibody
against SMemb diluted 1:200 in PBS with 1% ovalbumin. As a
negative control, sections were incubated in PBS with ovalbumin
without antibody. After rinsing in solution A, the sections were
incubated for two hours with biotinylated rabbit antiserum against
mouse immunoglobulins diluted 1:200. They were rinsed in solu-
tion A, and then incubated in horseradish peroxidase-labeled
streptavidin solution for one hour. The sections were rinsed and
fixed in 1% glutaraldehyde in PBS. After they were washed in PBS
and Tris buffer, peroxidase was detected by incubation in 0.1%
diaminobenzidine in Tris buffer for five minutes followed by the
addition of hydrogen peroxide to a final concentration of 0.01%
and subsequent incubation for 10 minutes. The sections were
post-fixed in 2% osmium tetroxide in 0.1 M sodium cacodylate
buffer containing 7.5% sucrose for one hour at 4°C, dehydrated in
* graded ethanol, and then embedded in epoxy resin. The ultrathin
sections were stained with lead citrate and observed with the
21 transmission electron microscope.
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Fig. 3. Immunoelectron micrographs of glomerul
in the anti-Thy 1 nephritis rats. In the controls,
SMemb reactive material (black dots) was
demonstrated only in epithelial cells (A)
(x2550). In the anti-Thy 1 nephritis rats,
SMemb was positive for mesangial, epithelial
and endothelial cells (B) (X3400).
Abbreviations are: Me, mesangial cell; Ep,
epithelial cell; En, endothelial cell.
standardize SMemb mRNA levels with pT7 mRNA levels in each
specimen. The antisense RNA probe was synthesized using the
Riboprobe Gemini System II kit (Promega Corp., Madison, WI,
USA). Hybridization with RNA samples, digestion with RNase,
and analysis on polyacrylamide gels were performed using the
ribonuclease protection assay RPA II kit (Ambion Inc.). The full
protection of riboprobe 1 with SMemb mRNA is 200nt. The fully
protected fragment of riboprobe 2 with pT7 mRNA is 8Ont.
Statistical analysis
All values are expressed as the mean standard error of the
mean. For the blood pressure, the urinaly protein excretion, and
the blood glucose concentration, statistical significance was eval-
uated using one-way analysis of variance with modified t-tests
performed using Bonferroni's method [28]. The semiquantitative
evaluation of the immunostaining was compared between groups
with non-parametric analysis based on the Kruskal-Wallis test.
Results
Anti-Thy 1 nephritis
Urinaiy protein excretion and light microscopy. In control rats,
the urinary protein excretion did not change throughout the
experiment. In anti-Thy I nephritis rats, the urinary protein
excretion was markedly increased at day 3, and then decreased
gradually from day 5 to day 21 (Table 1). At the light microscopy,
the total glomerular cellularity was decreased with acute mesan-
giolysis at day 3, and remarkably increased at day 5. At day 21, the
glomerular cellularity was decreased again with recovery of nor-
mal glomerular configuration. In a number of glomeruli, the
capillary tufts adhered to the Bowman's capsules.
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Table 2. Light microscopic changes of the nephrectomized rats and the
diabetic rats
Glomerular area
,jn2, io- Sclerosis indexa%
NX-4 SHAM
OP
7.35 0.15
8.80 023b
0 0
18 i'
NX-8 SHAM
OP
9.62 0.21c
15.95 032b,c
0 0
40 2h,c
NX-16 SHAM
OP
10.50 0.32e
17.01 0.42'
553 4'°
DM-4 Control
DM
6.14 0.14
799 019h
0 0b
DM-8 Control
DM
7.91 0.24"'
11.44 024b,c
4 l20 i"'
(N = 5).Valucs are mean SEM
a Percentage of glomerular cross sections with focal or global glomeru-
lar sclerosis
hp < 0.001 vs. control
P < 0.001, 4 vs. 8 weeks
' P < 0.01, 4 vs. 8 weeks
°P < 0.05, 8 vs. 16 weeks
Immunohistochemistty. Representative glomeruli stained for
SMemb or cs-SM actin are shown in Figure 1. In the anti-Thy 1
nephritis rats at days I and 3, SMemb was slightly expressed in
glomerular epithelial cells, but not in mesangial cells. At day 5,
SMemb was newly expressed in mesangial cells, and then ex-
pressed in diffuse and nodular patterns in mesangial areas at day
8. SMemb expression was still positive at day 21. Collecting ducts
were positive for SMemb in the disease models as well as in the
controls. In the control rats, epithelial cells were slightly positive
for SMemb. SMemb expression scores in the anti-Thy 1 nephritis
rats were higher than the controls at days 5, 8 and 21 (Fig. 2A).
Glomerular expression of cs-SM actin was already observed at day
1, and was greatest at day 8. However, cs-SM actin expression was
decreased earlier than SMemb at day 21 (Fig. 2B). Normal
glomeruli did not express cs-SM actin, although cs-SM actin
expression could be observed in the renal arteries and arterioles.
PCNA-positive cells were markedly increased in the anti-Thy 1
nephritis rats at day 5 (Fig. 2C).
Immunoelectron microscopy. In the control rats, we confirmed
only epithelial cells were positive for SMemb (Fig. 3A). In the
anti-Thy 1 nephritis rats, SMemb-positive cells were identified as
mesarigial, epithelial and endothelial cells (Fig. 3B).
mRNA expression of SMemb. SMemb mRNA were markedly
expressed in glomeruli from the anti-Thy 1 nephritis rats at day 5,
and decreased gradually at days 8 and 21 (ATS-5, -8, and -21 in
Fig. 6). In the control rats, SMemb mRNA was only slightly
detectable (Control in Fig. 6).
Other disease models
5/6 Nephrectomy. The blood pressure in the nephrectomized
rats was similar to that in the controls. The daily urinary protein
excretion in the nephrectomized rats was remarkably augmented
at week 4, and increased at week 16 (Table 1). Glomerular
hypertrophy and sclerosis were observed from week 4, and
progressed until week 16 (Table 2). In a number of glomeruli, the
glomerular tufts adhered to the Bowman's capsules with or
without segmental sclerosis. Representative glomeruli stained for
SMemb are shown in Figure 4 A-D. In the nephrectomized rats,
SMemb expression was comparable to the controls at day 3. At
day 10, SMemb was de novo expressed in mesangial cells, and
mesangial expression of SMemb was markedly increased at week
4. At weeks 8 and 16, SMemb was not expressed in mesangial
cells, but epithelial expression of SMemb was increased. In the
control rats, SMemb was slightly expressed in epithelial cells
throughout the experiment. SMemb expression scores were
higher in the nephrectomized rats than in the controls (NX4, -8,
and -16 in Fig. 5). a-SM actin expression was not detected in any
glomeruli of the disease models or the controls. The number of
PCNA-positive cells in the nephrectomized rats was increased at
day 10 (not shown). Immunoelectron microscopy confirmed
SMemb expression in mesangial cells at day 10 and week 4, and
enhanced expression in epithelial cells at weeks 8 and 16 (not
shown). SMemb mRNA was abundant in glomeruli at week 4, and
increased with the progression of disease stages (NX-4, -8, and -16
in Fig. 6).
Diabetes. The blood pressure in the diabetic rats was compara-
ble to that in the controls. The daily urinary protein excretion in
the diabetic rats was higher than the controls at weeks 4 and 8
(Table 1). Blood glucose levels had already increased by week 4
(426 27 mg/dl vs. 128 5 mg/dl in the control, P < 0.001).
Extracellular matrix expansion, glomerular hypertrophy and scle-
rosis were observed from week 4, and developed at week 8 (Table
2). Representative glomeruli are shown in Figure 4 E-H. In the
diabetic rats at days 3 and 10, SMemb expression was newly
observed in mesangial cells. At weeks 4 and 8, SMemb expression
was markedly increased in epithelial cells but not detected in
mesangial cells. In the control rats, SMemb was expressed in
epithelial cells but to a much lesser extent. SMemb expression
scores were higher in the diabetic rats than in the controls
throughout the experiment (DM4 and DM8 in Fig. 5). a-SM actin
was not expressed in any glomeruli. The number of PCNA-
positive cells in the diabetic rats was increased at day 3, and then
decreased (not shown). Immunoelectron microscopy confirmed
that SMemb expression in mesangial cells at days 3 and 10, and
enhanced expression in epithelial cells at weeks 4 and 8 (not
shown). SMemb mRNA was expressed at high levels at week 4,
and increased at week 8 (DM-4 and DM-8 in Fig. 6).
Fig. 4. Immunohistochemical glomerular staining for SMemb in the nephrectomized model (.4-D) and the diabetic (E-H). In the nephrectomized rats,
SMemb was expressed in mesangial cells at wcek 4 (A). At weeks 8 (B) and 16 (C), SMemb expression was enhanced in epithelial cells. In the
sham-operatcd rats (D), SMemb was slightly expressed in epithelial cells. In diabetes, SMemb was expressed in mesangial cells at day 10 (E). The
location of SMemb expression was changed to epithelial cells at week 4 (F) and 8 (G). In the controls (H), SMemb was slightly expressed in epithelial
cells (X260).
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Anti-GBM nephritis. The urinaly protein excretion in the GBM
nephritis rats was elevated at day 7 (Table 1). Mesangial expan-
sion, tuft adhesions to the Bowman's capsule, and glomerular
crescent formation were observed. Substantial amounts of
SMemb was expressed in glomerular epithelial cells, parietal
epithelial cells of the Bowman's capsule, and cellular crescents
(not shown). SMemb expression scores were higher in the GBM
nephritis rats than in the controls (GBM in Fig. 5). a-SM actin
was expressed in fibroblast-like cells surrounding the Bowman's
capsule, but not in glomerular cells. The number of PCNA-
positive cells in the GBM nephritis rats was comparable with the
controls (not shown). Immunoelectron microscopy revealed that
only epithelial cells expressed SMemb (not shown). SMemb
mRNA was markedly increased in the GBM nephritis rats (GBM
in Fig. 6).
In the four models, none of the glomeruli expressed 5M2, while
smooth muscles of the renal arteries and arterioles were strongly
positive for SM2.
Discussion
We demonstrated in the present study that a nonmuscie myosin
heavy chain, SMemb, is induced in both mesangial and glomerular
epithelial cells with glomerular diseases. SMemb displays a dis-
tinct expression pattern from a-SM actin depending on the stage
or type of the glomerular disease, indicating usefulness of a
nonmuscle myosin isoform in diagnosis as well as pathophysiolog-
ical understanding of glomerulopathy.
The expression pattern of SMemb and a-SM actin in glomer-
ular cells is summarized in Table 3. In the control rats, epithelial
cells slightly expressed SMemb. In the anti-Thy I nephritis rats,
SMemb expression was enhanced in epithelial cells and newly
observed in mesangial cells. SMemb appeared later than a-SM
actin and continued to be expressed after day 21. In the ncphrec-
tomized model and the diabetic rats, SMemb expression was
newly observed in mesangial cells at earlier stages, but at later
stages, remarkably enhanced in epithelial cells. In the anti-GBM
nephritis rats, the expression of SMemb was increased in epithe-
hal cells. a-SM actin expression was only detected in the anti-Thy
1 nephritis rats.
SMemb is abundantly expressed in embryonic smooth muscles,
in proliferating smooth muscle cells of experimental atheroscle-
rotic or arteriosclerotic lesions, and in cultured smooth muscle
cells [15, 16]. SMemb is also expressed in other mesenchymal
cells; cultured fibroblasts, myocardium with acute rejection in
cardiac transplantation, and hypervascular lesions of hepatic cell
carcinoma (unpublished observations). Because SMemb is thus
considered to be expressed in activated mesenchymal cells in
general, we expected the expression of SMemb to be useful in
identifying activated glomerular cells in glomerulopathy. In the
present study, we define the activated mesangial and epithelial
cells as those cells that change the phenotypes and express
SMemb.
Single injection of anti-Thy 1.1 serum caused transient mesan-
gial cell proliferation and massive proteinuria. SMemb expression
was enhanced both in mesangial cells and epithehial cells, which
was confirmed by immunoelectron microscopy and RNase pro-
tection assay. In this model, the disease is characterized by direct
binding of the antibody to mesangial cells, and mesangial cells
were considered to be selectively damaged [1, 29]. However, at the
ultrastructual level, Bagchus et al have reported that epithelial
cells were also damaged with an extensive effacement of foot
processes [30]. Our present results also indicate that both mesan-
gial and epithelial cells change their phenotypes in this model.
In the anti-Thy 1 nephritis rats, both SMemb and a-SM actin
were expressed in mesangial cells, but in a different way. The
expression of SMemb became significant later than day 5, and
remained positive after day 21 (Fig. 2A). On the other hand,
a-SM actin started to be expressed at day 1 with mesangial cell
proliferation, increased until day 8, and then disappeared after
day 21 (Fig. 2B). Along with the progression and regression of the
disease, the mesangial cell revealed transitional expression from
a-SM actin to SMemb dominant expression pattern. In this
model, there was a clear dissociation between the course of acute
nephritis and SMemb expression pattern. At day 21, glomerular
cells revealed a persistent increase in SMemb expression when
glomerular damage (that is, proteinuria or mesangial cell prolif-
eration) was recovering. The healing process of transient injury
involves a well-coordinated cascade of cellular and molecular
events, consisting of three stages: an inflammatory stage, prolif-
erative stage, and remodeling stage [31]. Thus, in this model, the
increased expression of SMemb in glomeruli may be associated
with the tissue remodeling after proliferation.
These features of SMemb expression pattern were also ob-
served in the early stage of the nephrectomized model and the
diabetic. In the nephrectomized rats, PCNA-positive cells were
increased in glomeruli at day 10, and SMemb was newly expressed
in mesangial cells at day 10 and week 4. In the diabetic rats, the
number of PCNA-positive cells was greatest at day 3, and after
proliferation, SMemb was markedly expressed in mesangial cells
at day 10. Thus, we assume that mesangial expression of SMemb
in the early stage of these models also reflects an overall repara-
tive process.
In the nephrectomized rats, the location of SMemb expression
was changed from mesangial cells to epithelial cells at week 8,
which was supported by immunoelectron microscopy. At week 8,
the expression of SMemb was increased in epithelial cells along
**3
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Rat model
Fig. 5. Semiquantitative evaluation of immunohistochemistiy for SMemb in
the nephrectomized rats, the diabetic rats, and the anti-GBM rats. SMemb
expression scores in all models (shaded column) (N = 5) were higher than
in the control groups (unshaded column) (N = 5). Abbreviations are the
same as in Table I. *p < 0.05, **p < 001.
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Fig. 6. RNase protection assay of total glomerular RNA forSMernb gene expression. RNA probe (left), RNA samples from the control rat, cultured rat
fibroblast, the nephrectomized rat at weeks 4, 8, 16, the diabetic rat at weeks 4, 8, the anti-Thy 1 nephritis rat at days 5, 8, 21, and the anti-GBM nephritis
rat. The 267nt band indicates RNA probe, and the 200nt band indicates SMemb mRNA. The human ribosomal RNA represented by 8Ont bands was
determined as an internal control. All lanes contain 5 ig of RNA.
Table 3. The expression of SMemb and a-SM actin in mesangial and
glomerular epithelial cells in various glomerular diseases
SMemb a-SM
Mesangial
actin
EpithelialMesangial Epithelial
cell cell cell cell
Normal — — —
Anti-Thy 1 nephritis + + + + —
5/6 Nephrectomy +—— — —
— —
— + — —
with severe glomerular hypertrophy. In the previous reports using
electron microscopy, epithelial cell injury was developed with
glomerular hypertrophy, foot process effacement, and detachment
from GBM [7, 11]. Thus, the expression of SMemb at week 8 may
indicate progressive epithelial cell injury caused by mechanical
stress.
By RNase protection assay in the nephrectomized rats, SMemb
mRNA showed the greatest increase at week 16, when SMemb
expression score was decreasing by immunohistochemistry. At
week 16, glomerular hypertrophy progressed and thus epithelial
expression of SMemb continued to increase in nonsclerotic gb-
meruli. Accordingly, SMemb mRNA was greatest at week 16.
However, at the light microscopy, SMemb expression score was
evaluated by counting all glomeruli, including sclerosing glomeruli
where SMemb was not expressed. Thus, SMemb expression score
was decreased when glomerular sclerosis progressed at week 16.
In diabetes, the expression pattern of SMemb was similar to the
nephrectomized rats, but epithelial expression was enhanced
earlier than the nephrectomized rats. The glomerular epithelial
cells are known to be injured at the onset of metabolic glomerular
diseases including diabetes; ballooning of epithelial cell or flat-
tening of foot processes was observed by transmission electron
microscopy [32]. Therefore, we theorize that SMemb is also useful
to detect epithelial cell injury induced by metabolic disorders.
In the anti-GBM nephritis rats, SMemb expression was en-
hanced in gbomerular epithelial cells and parietal epithelial cells
of the Bowman's capsule, which was confirmed by immunoelec-
tron microscopy. The previous study using transmission electron
microscopy described epithelial cell injury at the ultrastructural
level in this model as the complete detachment of the epithelial
cell from GBM, and prominent development of stress fibers in
foot processes of parietal epithelial cells connecting to the de-
nuded GBM [33]. The expression of SMemb in this model may
indicate the epithelial cell response to the immune-induced
gbomerular damage.
In the present study, a-SM actin was not expressed in any
glomeruli of nephrectomized model or the diabetic. However,
recent studies proposed that a-SM actin is newly expressed in
mesangial cells of these two models [34, 35]. The reason for lack
of a-SM actin expression in the present study is not clear, but the
difference of fixation or antibody may have caused this dissocia-
tion. Our results suggest that glomerular expression of a-SM actin
may be only limited to mesangial cell activation.
On the other hand, SMemb expression was not limited to
mesangial cells, but observed in both mesangial and epithelial
cells in the present study. It has been reported that epithelial cells
change the phenotypes and extensively express SMemb in many
disease models including puromycin nephrosis rats [36]. In various
types of gbomerulopathy, the epithelial cell has been reported to
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be damaged with effacement of foot processes [9] and with the
denudation of GBM, leading to high permeability to macromol-
ecules and eventually to glomeruloscierosis [37, 381. Thus, by the
inimunostaining for SMemb, we found that epithelial cell activa-
tion is a frequent pathological event, and may be closely related to
the progression of glomerular diseases.
To detect epithelial cell injury, several markers such as SPARC
(osteonectin) or desmin have been proposed [391. However, these
markers have some limitation because enhanced expression of
SPARC was observed only in the complement-mediated glomer-
ular diseases, and desmin was not expressed in the anti-Thy 1
nephritis model. In contrast, we demonstrated that SMemb was
expressed in any form of epithelial cell injury, including mechan-
ical injury by glomerular hypertrophy, metabolic injury, and
immune-induced injury, showing its usefulness to sensitively de-
tect various glomerular diseases.
In conclusion, glomerular cells (that is, mesangial and glomer-
ular epithelial cells) change their phenotypes differently over the
course of glomerular diseases. These phenotypic changes could be
revealed by the combined staining for SMemb and a-SM actin.
Further studies on the functional significance of the nonmuscie
myosiri expression in glomerular cells and the molecular mecha-
nisms controlling the nonmuscle myosin gene expression will
greatly enhance the understanding of the pathophysiology of
glomerular diseases.
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